Evidence map›Paper›PMID 35937598›Full record

ArticleFrontiers in surgery2022

Assessment of a novel smartglass-based point-of-care fusion approach for mixed reality-assisted targeted prostate biopsy: A pilot proof-of-concept study.

P Sparwasser, M Haack, L Frey, K Boehm, C Boedecker, T Huber, K Stroh, M P Brandt, R Mager, T Höfner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. HoloLensTherapeutic advances in urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

P SparwasserDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
M HaackDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
L FreyDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
K BoehmDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
C BoedeckerDepartment of General, Visceral and Transplant Surgery, University Medical Center Johannes Gutenberg University, Mainz, Germany.
T HuberDepartment of General, Visceral and Transplant Surgery, University Medical Center Johannes Gutenberg University, Mainz, Germany.
K StrohDepartment of Radiology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
M P BrandtDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
R MagerDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
T HöfnerDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
I TsaurDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
A HaferkampDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
H BorgmannDepartment of Urology, University Medical Center Johannes Gutenberg University, Mainz, Germany.
Johannes Gutenberg University Mainz · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEMedizinische Hochschule Brandenburg Theodor Fontane · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: While several biopsy techniques and platforms for magnetic resonance imaging (MRI)-guided targeted biopsy of the prostate have been established, none of them has proven definite superiority. Augmented and virtual reality (mixed reality) smartglasses have emerged as an innovative technology to support image-guidance and optimize accuracy during medical interventions. We aimed to investigate the benefits of smartglasses for MRI-guided mixed reality-assisted cognitive targeted biopsy of the prostate. Methods: For prospectively collected patients with suspect prostate PIRADS lesions, multiparametric MRI was uploaded to a smartglass (Microsoft® Hololens I), and smartglass-assisted targeted biopsy (SMART TB) of the prostate was executed by generation of a cognitive fusion technology at the point-of-care. Detection rates of prostate cancer (PCA) were compared between SMART TB and 12-core systematic biopsy. Assessment of SMART-TB was executed by the two performing surgeons based on 10 domains on a 10-point scale ranging from bad (1) to excellent (10). Results: SMART TB and systematic biopsy of the prostate were performed for 10 patients with a total of 17 suspect PIRADS lesions (PIRADS 3, Conclusion: SMART TB has the potential to increase accuracy for PCA detection and might enhance cognitive MRI-guided targeted prostate biopsy in the future.

Indexed as

augmented realityhololensmixed realityprostate biopsyprostate cancersmartglass

Identifiers

PMID35937598
PMCPMC9354482
OpenAlexW4286717314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.